| 5/3/06 |
Merrimack Pharmaceuticals Names Fazal Khan, Ph.D., Vice President of Manufacturing |
| 4/19/06 |
Merrimack Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093 in Patients with Psoriasis |
4/3/06
|
Merrimack Pharmaceuticals Raises $65 Million in Private Financing |
| 2/28/06 |
Merrimack Pharmaceuticals Announces the Addition of Barrett Rollins, MD, PhD to its Scientific Advisory Board |
| 10/19/05 |
Merrimack
Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093
in Patients with Rheumatoid Arthritis |
| 10/13/05 |
Merrimack Pharmaceuticals
Initiates Enrollment in a Phase 2 Study of MM-093 in Patients
with Psoriasis |
| 5/24/05 |
Merrimack Pharmaceuticals
Announces the Addition of Two New Members to its Scientific
Advisory Board. |
| 5/3/05 |
Merrimack Pharmaceuticals
Appoints Gary L. Crocker as Chairman of the Board. |
| 4/20/05 |
Merrimack Pharmaceuticals
Closes on $37 Million of Series D Equity and Loan Financing. |
| 3/3/05 |
Merrimack Pharmaceuticals
Initiates Enrollment in a Phase II Study of MM-093 in Patients
with Rheumatoid Arthritis. |
| 8/25/04 |
Merrimack
Pharmaceuticals Completes Enrollment For Phase IIa Study of
MM-093 in Patients with Rheumatoid Arthritis. |
| 7/20/04 |
Merrimack Pharmaceuticals
Names Dr. Brian L. Hamilton Vice President of Clinical and Regulatory
Affairs. |
| 6/1/04 |
Merrimack Pharmaceuticals
Begins Exploratory Collaboration with Novartis Institutes for
Biomedical Research. |
| 5/4/04 |
Merrimack Pharmaceuticals
Welcomes Gary L. Crocker to the Board of Directors. |
| 5/4/04 |
Merrimack Pharmaceuticals
Closes $28 Million in Series C Financing Round. |
| 3/25/04 |
Merrimack Pharmaceuticals
Awarded Second SBIR Grant. |
| 2/4/04 |
Merrimack Pharmaceuticals
Names Vincent F. Simmon as Chief Operating Officer. |
| 1/29/04 |
Merrimack Awarded SBIR
Grant for Cancer Drug Discovery. |
| 12/15/03 |
GTC Biotherapeutics
Takes Equity Position in Merrimack Pharmaceuticals as MM-093
Development Advances. |
| 11/19/03 |
Merrimack Pharmaceuticals
Completes Dosing in Phase I Study of Immunomodulator, MM-093. |
| 7/29/03 |
Merrimack Pharmaceuticals
Initiates Phase I Study of Immunomodulator, MM-093. |
| 1/3/03 |
GTC Biotherapeutics and Merrimack
Pharmaceuticals expand relationship to include rhAFP clinical
grade purification. |
| 10/23/02 |
GTC Biotherapeutics
and Merrimack Pharmaceuticals to Begin rhAFP Clinical Production. |
| 3/26/02 |
Merrimack Pharmaceuticals
elects Gary Frashier as Chairman of the Board of Directors. |
| 3/19/02 |
Merrimack Pharmaceuticals
welcomes Robert H. Rubin, MD to the Board of Directors. |
| 2/26/02 |
U.S. composition-of-matter
patent secures Merrimack Pharmaceuticals' rights to recombinant
human alpha-fetoprotein. |
| 2/20/02 |
Merger closes between Merrimack
Pharmaceuticals and Atlantic Biopharmaceuticals. |
| 9/4/01 |
Atlantic Biopharmaceuticals
names James Scibetta Executive Vice President and Chief Financial
Officer. |
